What does this research mean for the field?

Q: What does this research mean for the field?

The Ki-67 proliferation index is an independent prognostic marker for overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

December 12, 2007BloodOpen Access

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

View Full Paper

Ask AI

Bookmark

Why the study?

Does the Ki-67 index predict overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy?

Population

249 advanced-stage mantle cell lymphoma (MCL) patients treated within randomized trials

Comparison

Ki-67 index assessment at primary diagnosis in… vs Different Ki-67 index groups

Design

Cohort

Authors

ODOlaf DetermannInstitut für Hämatopathologie Hamburg EHEva HosterZimmer Biomet (Netherlands)GOGerman OttBoston University

Discussion

Member takes

Implication

Ki-67 may refine prognostication in advanced MCL on anti-CD20 therapy; extends independent value but leaves open therapeutic implications.

Structured PICO

Does the Ki-67 index predict overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy?

Population

249 advanced-stage mantle cell lymphoma (MCL) patients treated within randomized trials

Intervention

Ki-67 index assessment at primary diagnosis (prognostic marker evaluation) in patients treated with CHOP or R-CHOP (anti-CD20 therapy)

Comparator

Different Ki-67 index groups (<10%, 10% to <30%, and ≥30%)

Outcome

Overall survivalhard clinical

The Ki-67 index remains an important independent prognostic marker for overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 therapy.

Cite This Study

Determann et al. (2007) studied this question.

synapsesocial.com/papers/6a1bc2a25b8f4ede65a8f8a7 https://doi.org/10.1182/blood-2007-10-117010

View Full Paper

Ask AI

Bookmark

Implication

Ki-67 may refine prognostication in advanced MCL on anti-CD20 therapy; extends independent value but leaves open therapeutic implications.

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider